{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:13:47Z","timestamp":1788178427943,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115208","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:02:17Z","timestamp":1785996137000},"page":"115208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The use of alkalizers in sodium caprate-based tablets for oligonucleotide oral delivery"],"prefix":"10.1016","volume":"227","author":[{"given":"Sydney","family":"Marcy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleika","family":"Semling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Ingerslev","family":"Blaabjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-9997","authenticated-orcid":false,"given":"Felipe","family":"Varum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1461-4938","authenticated-orcid":false,"given":"Marc","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115208_b0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/endrev\/bnaa029","article-title":"Making, cloning, and the expression of human insulin genes in bacteria: the path to Humulin","volume":"42","author":"Riggs","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejpb.2026.115208_b0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2026.115208_b0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","article-title":"Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts","volume":"101","author":"Moroz","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115208_b0020","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/ijms25020815","article-title":"The current and promising oral delivery methods for protein- and peptide-based drugs","volume":"25","author":"Nicze","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.mattod.2023.01.002","article-title":"Oral drug delivery platforms for biomedical applications","volume":"62","author":"Ouyang","year":"2023","journal-title":"Mater. Today"},{"key":"10.1016\/j.ejpb.2026.115208_b0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/children7120307","article-title":"An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics","volume":"7","author":"Dan","year":"2020","journal-title":"Children"},{"key":"10.1016\/j.ejpb.2026.115208_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113925","article-title":"Formulation strategies to improve the efficacy of intestinal permeation enhancers","volume":"177","author":"Maher","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115208_b0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2026.115208_b0045","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-enhancing effects of bile salts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115208_b0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00424-016-1902-x","article-title":"Targeting and alteration of tight junctions by bacteria and their virulence factors such as Clostridium perfringens enterotoxin","volume":"469","author":"Eichner","year":"2017","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"10.1016\/j.ejpb.2026.115208_b0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","article-title":"The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition","volume":"86","author":"Welling","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0060","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0022-3565(25)12150-2","article-title":"Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers","volume":"275","author":"Lindmark","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2026.115208_b0065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Anderson","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2026.115208_b0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/pathophysiology30030029","article-title":"Acromegaly: pathophysiological considerations and treatment options including the evolving role of oral somatostatin analogs","volume":"30","author":"Daniel","year":"2023","journal-title":"Pathophysiology"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115208_b0075","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115208_b0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/17425247.2021.1942838","article-title":"Transient Permeation Enhancer\u00ae (TPE\u00ae) technology for oral delivery of octreotide: a technological evaluation","volume":"18","author":"Brayden","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115208_b0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jps.21084","article-title":"Oral delivery of antisense oligonucleotides in man","volume":"97","author":"Tillman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00280-009-1038-1","article-title":"Oral administration of the GnRH antagonist acyline, in a GIPET\u00ae-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics","volume":"64","author":"Amory","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115208_b0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomized, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejpb.2026.115208_b0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115208_b0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2024.11.078","article-title":"Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: a preclinical and clinical study","volume":"378","author":"Niu","year":"2025","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115208_b0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejps.2009.07.011","article-title":"Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies","volume":"38","author":"Maher","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105685","article-title":"Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): isolated rat intestinal mucosae and sacs","volume":"158","author":"Twarog","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0120","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0125","doi-asserted-by":"crossref","first-page":"22521","DOI":"10.1038\/s41598-021-01750-0","article-title":"Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease","volume":"11","author":"Pechenov","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.115208_b0130","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s11095-022-03372-1","article-title":"Identification of a multi-component formulation for intestinal delivery of a GLP-1\/glucagon co-agonist peptide","volume":"39","author":"Tran","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2026.115208_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123680","article-title":"Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP\/GLP1 peptide in monkeys","volume":"650","author":"Tran","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0145","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1021\/la020672y","article-title":"Effect of premicellar aggregation on the pKa of fatty acid soap solutions","volume":"19","author":"Kanicky","year":"2003","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2026.115208_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/end.2019.0292","article-title":"Alkalinizing agents: a review of prescription, over-the-counter, and medical food supplements","volume":"34","author":"Stern","year":"2020","journal-title":"J. Endourol."},{"key":"10.1016\/j.ejpb.2026.115208_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221086457","article-title":"Antacids revisited: review on contemporary facts and relevance for self-management","volume":"50","author":"Garg","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejpb.2006.07.001","article-title":"pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations","volume":"65","author":"Riis","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2008.04.001","article-title":"Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release","volume":"129","author":"Tran","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115208_b0170","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/pharmaceutics16070866","article-title":"Formulation and evaluation of pH-modulated amorphous solid dispersion-based orodispersible tablets of Cefdinir","volume":"16","author":"Alhamhoom","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115208_b0175","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1023\/A:1026449527891","article-title":"Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine","volume":"17","author":"Baluom","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.31083\/ph.2012.1648","article-title":"Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybezoyl) amino] caprylate (SNAC)","volume":"67","author":"Bittner","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2026.115208_b0185","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.31920","article-title":"Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejpb.2026.115208_b0190","doi-asserted-by":"crossref","unstructured":"H. Javanbakht et al., Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo. Mol Ther Nucleic Acids. 1 (2018 Jun 1) 441-454. https:\/\/doi.org\/10.1016\/j.omtn.2018.02.005.","DOI":"10.1016\/j.omtn.2018.02.005"},{"key":"10.1016\/j.ejpb.2026.115208_b0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejpb.2018.05.029","article-title":"Development of stable liquid formulations for oligonucleotides","volume":"129","author":"Poecheim","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0200","first-page":"409","article-title":"A Britton-Robinson buffer of known ionic strength","volume":"64","author":"Mongay","year":"1974","journal-title":"Ann. Chim."},{"key":"10.1016\/j.ejpb.2026.115208_b0205","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jps.20932","article-title":"Microenvironmental pH modulation in solid dosage forms","volume":"96","author":"Badawy","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0210","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/jps.21052","article-title":"Measurement of surface pH of pharmaceutical solids: a critical evaluation of indicator dye-sorption method and its comparison with slurry pH method","volume":"97","author":"Pudipeddi","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfca.2020.103485","article-title":"The effects of gastric juice acidity on bioaccessibility of some elements in selected foods","volume":"90","author":"Karada\u015f","year":"2020","journal-title":"J. Food Compos. Anal."},{"key":"10.1016\/j.ejpb.2026.115208_b0220","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1023\/A:1015827908309","article-title":"Upper gastrointestinal (GI) pH in young, healthy men and women","volume":"7","author":"Dressman","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0225","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1021\/acs.molpharmaceut.5c00249","article-title":"Impact of permeation enhancers on the release of insulin from tablets in biorelevant media","volume":"22","author":"Fagan","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0230","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.molpharmaceut.1c00262","article-title":"Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using pH modifiers: a physiologically realistic mass transport analysis","volume":"18","author":"Salehi","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0235","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006. Impurities in New Drug Products Q3B(R2). ICH Harmonized Tripartite Guideline. https:\/\/database.ich.org\/sites\/default\/files\/Q3B%28R2%29%20Guideline.pdf."},{"key":"10.1016\/j.ejpb.2026.115208_b0240","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.xphs.2019.01.025","article-title":"Overcoming poor tabletability of bulky absorption enhancer by spray drying technology","volume":"108","author":"Fan","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0245","unstructured":"S.B. Jensen et al., Skibsted, Tablet formulation comprising semaglutide and a delivery agent, U.S. Patent US9993430B2, 2018."},{"key":"10.1016\/j.ejpb.2026.115208_b0250","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0255","unstructured":"Food and Drug Administration, US Department of Health and Human Services, 2018. Dissolution testing and acceptance criteria for immediate-release solid oral dosage form drug products containing high solubility drug substances: guidance for industry. https:\/\/www.fda.gov\/files\/drugs\/published\/Dissolution-Testing-and-Acceptance-Criteria-for-Immediate-Release-Solid-Oral-Dosage-Form-Drug-Products-Containing-High-Solubility-Drug-Substances-Guidance-for-Industry.pdf."},{"key":"10.1016\/j.ejpb.2026.115208_b0260","article-title":"An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery","author":"Bardonnet","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115208_b0265","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/jps.24365","article-title":"Animal farm: considerations in animal gastrointestinal physiology and relevance to drug delivery in humans","volume":"104","author":"Hatton","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115208_b0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejpb.2019.07.012","article-title":"Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions","volume":"142","author":"Roos","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0275","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/acs.molpharmaceut.1c00724","article-title":"Impact of intestinal concentration and colloidal structure on the permeation-enhancing efficiency of sodium caprate in the rat","volume":"19","author":"Berg","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115208_b0280","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/ph15121585","article-title":"Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejpb.2026.115208_b0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2024.11.036","article-title":"Salcaprozate-based ionic liquids for GLP-1 gastric delivery: a mechanistic understanding of in vivo performance","volume":"377","author":"Rebollo","year":"2025","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:16:11Z","timestamp":1788174971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"alternative-id":["S0939641126002298"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115208","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of alkalizers in sodium caprate-based tablets for oligonucleotide oral delivery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115208"}}